Atlas Trials

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT02058381 · COMPLETED

Trial details

NCT number
NCT02058381
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pre-menopausal Breast CancerPI3K Pathway Inhibition
Start date
2014-05-06
Primary completion
2018-06-19
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.